The harm here is the medical industry sticking with the amyloid hypothesis in the face of repeated and expensive failures. The funding needs to move on to some

The harm here is the medical industry sticking with the amyloid hypothesis in the face of repeated and expensive failures. The funding needs to move on to something that might actually work. Propping up these failed drugs with "what does it hurt" is in the way of getting an Alzheimer's drug that might actually benefit people.